Domain EYEION.com for sale! This premium domain is available now at Kadomain.com
It's not too late to turn it all around.View Entire Post ›
According to Instagram, Bieber counts the multitasking formula among her empties.View Entire Post ›
“I don’t know that I have ever heard a celebrity talk about a hot flash in the moment. Thank you for being so real.”View Entire Post ›
The Embryolisse Lait-Crème Concentré is a multi-tasking hidden gem of a facial cream.View Entire Post ›
After the model opened up about her experience being diagnosed with type 1 diabetes, we asked experts about the autoimmune condition, the differences between type 1 and type 2 diabetes, and how this diagnosis can change your life.View Entire Post ›
An acupuncturist explains how this scary-looking acupressure mat can help relieve back pain.View Entire Post ›
The Congressional Budget Office has estimated that permanently extending premium health subsidies would increase the number of insured people to 3.8 million by 2035 while also increasing the deficit by $349.8 billion over 10 years.
A Novo Nordisk-designed trial, conducted at 68 international hospitals, specialist clinics, and medical centers with investigators from University of Texas Southwestern Medical Center and other institutions, reports greater reductions with once-weekly semaglutide 7.2 mg than placebo in bodyweight, waist circumference, and HbA1c over 72 weeks.
On September 18th, the Centers for Disease Control and Prevention's vaccine advisory committee voted to make a significant change to the nation's childhood vaccine schedule during its first gathering since members were handpicked by Health and Human Services Secretary Robert F. Kennedy Jr.
The American Gastroenterological Association (AGA) has released a new clinical guideline with 12 conditional recommendations for diagnosing and managing gastroparesis, a serious and often debilitating disease. The guideline has been published in the journal Gastroenterology.
A study conducted by the Molecular Oncology Research Center (CPOM) at Hospital de Amor in Barretos (formerly Barretos Cancer Hospital) in the state of São Paulo, Brazil, has identified possible biomarkers that could guide the development of more personalized therapies for pediatric germ cell tumors (GCTs).
A US medical panel handpicked by President Donald Trump's health secretary made its first alteration to the standard childhood vaccine schedule on Thursday, as public health experts fear more changes that flout prevailing medical advice are in the pipeline.
Scientists have developed and tested a deep-learning model that could support clinicians by providing accurate results and clear, explainable insights—including a model-estimated probability score for autism.
The largest study on pregnant women with excessive nausea and vomiting (hyperemesis gravidarum) has identified increased risks of numerous neuropsychiatric and mental health outcomes. The study is published in the journal The Lancet Obstetrics, Gynaecology, & Women's Health.
The current process for managing sexual misconduct perpetrated by doctors in the UK requires major reform, say experts in The BMJ.
New research shows that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10–17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.
The global type 1 diabetes (T1D) burden continues to increase rapidly, driven by rising cases, aging populations, improved diagnosis and falling death rates, according to the results of a new modeling study presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna (15–19 Sept).
New research (the Ver-A-T1D trial) presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15–19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.
In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the body's own insulin production and slow the progression of type 1 diabetes (T1D) in people recently diagnosed with the condition.